Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 11—November 2025
Synopsis
Trichosporon austroamericanum Infections among Hospitalized Patients, France, 2022–2024
Emilie Burel, Catherine Sartor, Valérie Moal, Vincent Bossi, Jacques Sevestre, Justine Solignac, Rémi Charrel, Marie Desnos-Ollivier, Stéphane Ranque, and Estelle Menu
Table 1
Characteristics of patients from investigation of Trichosporon austroamericanum infections among hospitalized patients, France, 2022–2024*
| Characteristics | Sample no. |
|||||
|---|---|---|---|---|---|---|
| L0221 | L0385 | L0399 | L0419 | L0445 | L0458 | |
| Patient location | ||||||
| Hospital | A | A | A | B | C | A |
| Hospital ward | ||||||
| Kidney transplantation unit | Y | Y | Y | N | N | Y |
| Cardiac surgery | N | N | N | Y | N | N |
| Gastrointestinal surgery |
N |
N |
N |
N |
Y |
N |
| Clinical signs at time of positive culture | ||||||
| Fever | Y | Y | N | N | N | N |
| Asthenia | Y | Y | N | Y | Y | N |
| Dyspnea | N | Y | N | N | Y | N |
| Digestive symptoms | N | N | N | N | Y | N |
| Scar dehiscence |
Y |
Y |
Y |
NA |
NA |
Y |
| Biology at time of positive culture | ||||||
| Creatinine, µmol/L | 271 | 128 | 103 | 177 | 80.7 | 216 |
| C-reactive protein, mg/L |
86 |
73 |
43 |
22 |
NP |
1.3 |
| Positive culture results | ||||||
| Date of first positive culture | 2022 Jul | 2023 Apr | 2023 Jun | 2023 Dec | 2024 Apr | 2024 Jun |
| Days after transplantation | 71 | 78 | 135 | NA | NA | 115 |
| No. positive samples | 4 | 11 | 1 | 5 | 3 | 1 |
| Blood | 0 | 11 | 0 | 5 | 0 | 0 |
| Scar swab | 3 | 0 | 0 | 0 | 0 | 0 |
| Abscess aspiration | 1 | 0 | 1 | 0 | 0 | 1 |
| Respiratory sample |
0 |
0 |
0 |
0 |
3 |
0 |
| Microbiology | ||||||
| Cryptococcal antigen | Positive | Positive | Positive | Negative | NP | Negative |
| Titer | 160 | 5,120 | 20 | – | – | – |
| Aspergillus antigen | Negative | NP | NP | NP | Negative | NP |
| Index |
0.04 |
– |
– |
– |
0.13 |
– |
| Outcome | ||||||
| Death within 90 d | N | N | N | Y | Y | N |
| No. days after first positive culture |
NA |
NA |
NA |
30 |
30 |
NA |
| Treatment | ||||||
| Posaconazole | N | Y | N | N | N | N |
| Voriconazole | Y | Y | Y | N | N | Y |
| Amphotericin B | N | Y | N | N | N | N |
| Surgical debridement | Y | Y | Y | NA | N | Y |
| Immunosuppressant reduction | Y | Y | N | NA | NA | Y |
*NA, not applicable; NP, not performed; –, no data.
Page created: September 18, 2025
Page updated: November 20, 2025
Page reviewed: November 20, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.